Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of WX390 plus toripalimab in STK11-mutant advanced gastric-type adenocarcinoma of the cervix
CTR20232293Phase 2Active
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of WXFL10030390 and toripalimab in gastric-type endocervical adenocarcinoma (GAS), sponsored by Shanghai Jiatan Pharmatech. Started Aug 2023; status: active.
02
Drugs
WXFL10030390toripalimab
03
Conditions
gastric-type endocervical adenocarcinoma (GAS)
Beyond the preview
Go deeper on CTR20232293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232293.